5i1d
From Proteopedia
(Difference between revisions)
m (Protected "5i1d" [edit=sysop:move=sysop]) |
|||
| Line 1: | Line 1: | ||
| - | '''Unreleased structure''' | ||
| - | + | ==CRYSTAL STRUCTURE OF HUMAN GERMLINE ANTIBODY IGHV3-23/IGKV4-1== | |
| + | <StructureSection load='5i1d' size='340' side='right' caption='[[5i1d]], [[Resolution|resolution]] 2.00Å' scene=''> | ||
| + | == Structural highlights == | ||
| + | <table><tr><td colspan='2'>[[5i1d]] is a 4 chain structure. This structure supersedes the now removed PDB entry [http://oca.weizmann.ac.il/oca-bin/send-pdb?obs=1&id=3qos 3qos]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5I1D OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5I1D FirstGlance]. <br> | ||
| + | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr> | ||
| + | <tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[5i15|5i15]], [[5i16|5i16]], [[5i17|5i17]], [[5i18|5i18]], [[5i19|5i19]], [[5i1a|5i1a]], [[5i1c|5i1c]], [[5i1e|5i1e]], [[5i1g|5i1g]], [[5i1h|5i1h]], [[5i1i|5i1i]], [[5i1j|5i1j]], [[5i1k|5i1k]], [[5i1l|5i1l]], [[4kmt|4kmt]]</td></tr> | ||
| + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5i1d FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5i1d OCA], [http://pdbe.org/5i1d PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5i1d RCSB], [http://www.ebi.ac.uk/pdbsum/5i1d PDBsum]</span></td></tr> | ||
| + | </table> | ||
| + | <div style="background-color:#fffaf0;"> | ||
| + | == Publication Abstract from PubMed == | ||
| + | The crystallization of 16 human antibody Fab fragments constructed from all pairs of four different heavy chains and four different light chains was enabled by employing microseed matrix screening (MMS). In initial screening, diffraction-quality crystals were obtained for only three Fabs, while many Fabs produced hits that required optimization. Application of MMS, using the initial screens and/or refinement screens, resulted in diffraction-quality crystals of these Fabs. Five Fabs that failed to give hits in the initial screen were crystallized by cross-seeding MMS followed by MMS optimization. The crystallization protocols and strategies that resulted in structure determination of all 16 Fabs are presented. These results illustrate the power of MMS and provide a basis for developing future strategies for macromolecular crystallization. | ||
| - | + | Protein crystallization with microseed matrix screening: application to human germline antibody Fabs.,Obmolova G, Malia TJ, Teplyakov A, Sweet RW, Gilliland GL Acta Crystallogr F Struct Biol Commun. 2014 Aug;70(Pt 8):1107-15. doi:, 10.1107/S2053230X14012552. Epub 2014 Jul 23. PMID:25084393<ref>PMID:25084393</ref> | |
| - | + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |
| - | + | </div> | |
| - | + | <div class="pdbe-citations 5i1d" style="background-color:#fffaf0;"></div> | |
| - | + | == References == | |
| + | <references/> | ||
| + | __TOC__ | ||
| + | </StructureSection> | ||
[[Category: Gilliland, G]] | [[Category: Gilliland, G]] | ||
| - | [[Category: Obmolova, G]] | ||
[[Category: Luo, J]] | [[Category: Luo, J]] | ||
| + | [[Category: Malia, T]] | ||
| + | [[Category: Obmolova, G]] | ||
| + | [[Category: Teplyakov, A]] | ||
| + | [[Category: Immune system]] | ||
| + | [[Category: Monoclonal antibody]] | ||
Revision as of 18:02, 26 February 2016
CRYSTAL STRUCTURE OF HUMAN GERMLINE ANTIBODY IGHV3-23/IGKV4-1
| |||||||||||
